OBJECTIVE： To investigate the clinical efficacy of itopride combined with esomeprazole magnesium in the treatment of esophageal motility dysfunction-induced gastroesophageal reflux disease （GERD）. METHODS： A total of 100 patients with esophageal motility dysfunction-induced GERD were selected from our hospital during Sept. 2015-Sept. 2016， and then divided into control group and observation group according to random number table， with 50 cases in each group. Control group was given Esomeprazole magnesium enteric-coated tablets 40 mg， po， qd. Observation group was additionally given Itopride hydrochloride tablets 50 mg， po， tid， on the basis of control group. Both groups received treatment for consecutive 6 weeks. Clinical efficacies of 2 groups were observed， and symptom scores， LES resting pressure， liquid and solid swallowing and peristaltic pressure of esophageal body were observed before and after treatment. The occurrence of ADR was recorded. RESULTS： Total response rate of observation group was 94.0％， which was significantly higher than 78.0％ of control group， with statistical significance （P＜0.05）. Before treatment， there was no statistical significance in symptom scores， LES resting pressure， liquid and solid swallowing or peristaltic pressure of esophageal body between 2 groups （P＞0.05）. After treatment， symptom scores of 2 groups were decreased significantly， and observation group was significantly lower than control group， with statistical significance （P＜0.05）. Compared with before treatment， LES resting pressure of observation group was increased significantly， and significantly higher than that of control group， with statistical significance （P＜0.05）. Success rate of liquid swallowing increased significantly in 2 groups， and that of observation group was significantly higher than that of control group， with statistical significance （P＜0.05）. Success rate of solid swallowing， liquid and solid peristaltic pressure of esophageal body （near segment， middle segment and far segment） in control group were higher than before treatment， without statistical significance （P＞0.05）. Success rate of solid swallowing，  liquid and solid peristaltic pressure of esophageal body （near segment， middle segment and far segment） in observation group were significantly higher than before treatment， and significantly higher than control group at corresponding period， with statistical significance （P＜0.05）. No obvious ADR was found in 2 groups during treatment. CONCLUSIONS： For esophageal motility dysfunction-induced GERD， itopride combined with esomeprazole magnesium can significantly improve clinical symptom， effectively increase LES resting pressure， strengthen esophageal motor function， improve success rate of esophageal swallowing and enhance anti-gastroesophageal reflux ability with good safety.